Table 1.

Detailed summaries of the enrolled studies

Authors, year	Region	Type of study	The proportion of PWID with LP among all HIV-infected PWID (95% CI)	The proportion of PWID with LP to all HIV-infected patients (95% CI)	The odds of LP in PWID compared to MSMs (95% CI)	The odds of advanced disease in PWID compared to MSMs(95% CI)	Quality score	References
Hu et al., 2019	China	cross-sectional	55 (52.4–58.4)	1.89 (1.74–2.04)	1.39 (1.2–1.67)	2.06 (1.73–2.45)	7*	[17]
Wójcik-Cichy et al., 2018	Poland	retrospective	80 (67.57–89.77)	17.37 (12.96–22.55)	3.49 (1.63–7.48)		8*	[18]
Brannstrom et al., 2015	Sweden	cohort	42.8 (24.46–62.82)	36.3 (18.9–62.5)	1.11 (0.49–2.49)		8*	[19]
Wilton et al., 2018	Canada	cohort	47.65 (39.41–55.98)	57.3 (45–71.7)	0.94 (0.66–1.34)		8*	[20]
Camoni et al. 2013	Italy	cohort	59.76 (54.23–65.11)	64.1 (55.7–73.3)	1.86 (1.46–1.67)		8*	[21]
Siwak et al., 2019	Poland	cross-sectional	66.42 (62.69–70.00)	19.87 (18.23–21.58)	2.02 (1.68–2.42)	2.68 (2.24–3.22)	8*	[22]
Sobrino-Vegas et al., 2012	Spain	cohort	26.64 (23.08–30.45)	12.31 (10.54–14.26)	0.72 (0.58–0.90)		8*	[23]
Op de Coul et al., 2014	Netherlands	cohort	78.77 (75.29–81.97)	42.5 (38.8–46.4)	2.53 (2.07–3.09)	2.9 (2.35–3.58)	8*	[24]
Vives et al., 2012	Spain	cohort	55.7 (51.78–59.74)	13.35 (12.06–14.71)	1.66 (1.36–2.03)		8*	[25]
Metallidis et al., 2012	Greece	retrospective	–	–	2.19 (0.98–4.9)	2.23 (1.02–4.86)	8*	[26]